TRIAL DETAIL
Administration of BIIB028 to Subjects With Solid Tumors
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Administration of BIIB028 to Subjects With Solid Tumors |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 06/01/2008 |
Age of Trial (yrs) 16.4 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
HSP90 inhibitor |
|||
Strategy: |
Destroy KIT |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
121ST101 |
|||
Sponsor: |
Biogen Idec |
|||
Patient Contact: |
Biogen Idec
oncologyclinicaltrials@biogenidec.com
|
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Intravenous |
|||
Trial Notes: |
Drug: BIIB028 IV infusion administered twice weekly until disease progression or unacceptable toxicity. |
|||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
1505 Holcombe Blvd. |
Houston |
TX |
77030 |
USA |
|
477 N. El Camino Real |
Encinitas |
CA |
92024 |
USA |
|
Los Angeles |
CA |
USA |